polymerization

Tubulin polymerization-IN-43 is an inhibitor of tubulin polymerisation.Tubulin polymerization-IN-43 has multiple effects, disrupting the cellular microtubule network by targeting the colchicine locus and promoting cell cycle arrest and apoptosis in leukaemia cells. Tubulin polymerisation-IN-43 has multiple effects, promoting leukaemia cell cycle arrest in G2/M phase and apoptosis by targeting Colchicine sites to disrupt the cellular microtubule network.

Tubulin polymerization-IN-29 is a potent inhibitor of microtubule protein polymerization and shows potent anti-proliferative effects.Tubulin polymerization-IN-29 induces cell cycle arrest in HeLa cells at G2/M phase.

Tubulin polymerization-IN-45, a tubulin-targeting agent, inhibits tubulin polymerization by binding to tubulin's colchicine site, inducing apoptotic cell death in hepatocellular cancer (HCC) cells [1].

Tubulin polymerization-IN-46 (compound 9q) is a microtubule tubulin inhibitor that obstructs tubulin polymerization, triggers apoptosis, and arrests MCF-7 breast cancer cells in the G2 M phase, demonstrating potent anti-proliferative activity with an IC50 of 10 nM [1].

Tubulin polymerization-IN-35 is [1,2] an inhibitor of oxazolylisoindole microtubulin polymerization that acts highly selectively on the marginal zone lymphoma VL51 cell line.

Tubulin polymerization-IN-14 (Compound 20a) is a tubulin polymerization inhibitor (IC50 = 3.15 μM) that demonstrates strong anti-vascular and anticancer activities, including inducing cancer cell apoptosis [1].

Tubulin polymerization-IN-39, a tubulin polymerization inhibitor with an IC50 of 4.9 μM, targets the colchicine-binding site to hinder tubulin polymerization. This compound effectively suppresses cancer cell proliferation.

Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor that impedes cancer cell proliferation, making it a valuable tool for researching cancers, including lymphoma.

Tubulin polymerization-IN-26 (compound 12h) is a chemical compound that inhibits the polymerization of microtubulin by binding to the colchicine binding site, with an IC50 value of 4.64 μM. It can induce apoptosis and inhibit cell metastasis, making it a valuable compound for researching lung cancer [1].

Tubulin Polymerization-IN-51 (compound 7u) serves as a tubulin polymerization inhibitor, exhibiting an IC50 range of 2.55 - 17.89μM against SK-Mel-28 cells, and is applicable in cancer research [1].

Tubulin polymerization-IN-9, a potent inhibitor of tubulin (IC50: 1.82 μM), arrests the cell cycle of K562 cells in the G2 M phase, induces apoptosis and mitochondrial depolarization, and exhibits strong anti-vascular and anti-tumor effects.

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

Tubulin polymerization-IN-52 (compound SC23) effectively inhibits tubulin polymerization with an IC50 value of 2.9 μM [1].

Tubulin polymerization-IN-6 (compound 5f) is a potent tubulin polymerization inhibitor with an IC50 of 1.09 μM. It inhibits cell migration and tube formation, exhibits anti-angiogenic properties, and effectively hinders tumor growth in HT29 xenograft Balb c nude mice [1].

Tubulin polymerization-IN-31 (Compound 4c) is an inhibitor of tubulin polymerization with an IC50 value of 3.64 μM [1], exhibiting antitumor activity and inducing apoptosis in cancer cells.

Tubulin polymerization-IN-8 (compound IIc) is a potent inhibitor of tubulin polymerization, inducing concentration-dependent cell cycle arrest at the G2 M phase in HCT116 tumor cells and significantly inhibiting tubulin polymerization with an IC50 of 12.7 μM, showing potential for cancer research [1].

Tubulin polymerization-IN-33, an [1,2] inhibitor of oxazoloisoindole microtubulin polymerization, is an effective anti-proliferative agent for NCI series cancer cells.

Tubulin polymerization-IN-10 is a highly potent inhibitor of tubulin polymerization with an IC50 value of 4.25±0.75 μM, exhibiting significant anti-tumor properties [1].

Tubulin polymerization-IN-53 (compound 4b) inhibits β-tubulin polymerization, arrests the cell cycle at the G2 M stage, and demonstrates antiproliferative efficacy against the MDA-MB-231 cell line, with an IC50 value of 3.24 μM [1].

Tubulin polymerization-IN-21 is an inhibitor of microtubulin polymerization that disrupts cell integrity and affects glucose metabolism, and has anticancer effects.

Tubulin polymerization-IN-25 is a selective, dual tubulin polymerization (IC50: 1.11 μM) and farnesyl transferase (FTase) (IC50: 0.39 μM) inhibitor. polymerization-IN-25 exhibits cytotoxicity against cancer cells and blocks cell proliferation.

Tubulin Polymerization-IN-2 is a powerful anticancer agent that targets β-tubulin, exhibiting an IC 50 of 0.92 μM. It demonstrates promising efficacy against a range of cancer cell lines including leukemia, non-small cell lung, renal, prostate, and breast cancers [1].

Tubulin polymerization-IN-4 is an effective inhibitor of tubulin polymerization (IC50=4.6 μM）。 Tubulin polymerization-IN-4 can destroy tubulin polymerization, block cell cycle at G2 M phase, induce apoptosis, and inhibit cell cloning and migration. Tubulin polymerization-IN-4 can also damage the vascular system.

Tubulinpolymer-in-44 (compound 7w) inhibits Tubulin with an IC50 of 0.21 μM and induces apoptosis by arresting the G2 M phase, making it useful for cancer research.

Tubulin polymerization-IN-24 (compound HMBA) is a potent inhibitor of tubulin polymerization, increasing GTP hydrolysis rate and inhibiting microtubule assembly. It induces apoptosis and cell cycle arrest in the G2 M phase, and inhibits the proliferation of MCF-7 cells [1].

Tubulin polymerization-IN-30 (compound 6e) is a potent inhibitor of tubulin polymerization that disrupts intracellular microtubule organization and arrests the cell cycle at the G2 M phase. Tubulin polymerization-IN-30 exhibits high potency against cancer cell lines HeLa, SGC-7901, and A549, with IC 50 values of 0.403, 2.16, and 2.21 μM, respectively.

Tubulin polymerization-IN-34 is an inhibitor of [1,2] oxazolylisoindole-based microtubule polymerization and demonstrates high selectivity for marginal zone lymphoma VL51 cell lines.

Tubulin polymerization-IN-13 (Compound 4f) is a potent tubulin polymerization inhibitor with an IC50 of 0.37 μM, demonstrating significant anti-proliferative effects on cancer cells, inducing apoptosis, and exhibiting potential antivascular activity [1].

Tubulin polymerization-IN-22 arrests cell cycle at G2 M phase as well as induces apoptosis. Tubulin polymerization-IN-22 is an inhibitor of tubulin polymerization (IC 50 = 8.1 μM) [1].

Tubulin polymerization-IN-27 (compound 5j) is a tubulin polymerization inhibitor that arrests the cell cycle at the G2 M phase and induces apoptosis [1].

Tubulin Polymerization-IN-50 (compound 7n) serves as an inhibitor of tubulin polymerization, exhibiting an IC50 of 5.05 μM in SK-Mel-28 cells and inducing cell cycle arrest at the G2/M phase [1].

Tubulin polymerization-IN-48 (Compound 4k) is a tubulin polymerization inhibitor that moderately disrupts the microtubule network and impedes the proliferation of neuroblastoma cancer cells, with IC50 values of 79 nM and 165 nM for the Chp-134 and Kelly cell lines, respectively [1].

Tubulin Polymerization-IN-40 is an acridane-based inhibitor that potently disrupts tubulin polymerization, exhibiting an IC50 of 1.5 μM. It halts cancer cell progression at the G2/M phase, triggers apoptosis, and possesses anti-cancer properties along with immunopotentiating effects [1].

Tubulin polymerization-IN-55 is a potent Tubulin Polymerization inhibitor with potential anti-angiogenic and anti-tumor activity, demonstrating anti-proliferative effects against A549, K562, HepG2, MDA-MB-231, and HFL-1.

Tubulin Polymerization-IN-56 (compound 8l), an indazole derivative, potently inhibits tubulin polymerization by targeting the colchicine site, which induces cell cycle arrest and apoptosis. Additionally, this compound diminishes cell migration and significantly inhibits tumor growth in vivo [1].

Tubulin polymerization-IN-36 is able to be used in cancer research, for example, lymphomas. Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding, that is an inhibitor of tubulin polymerization with IC50 of 2.8 μΜ[1].

Tubulin polymerization-IN-15 (compound 4) is a potent tubulin polymerization inhibitor with significant potential in cancer research [1].

Tubulin polymerization-IN-3 is a potent inhibitor of microtubulin polymerization (IC50: 3.84 μM) and induces apoptosis in colon cancer cells.

Tubulin polymerization-IN-49 (compound 12d), a potent tubulin polymerization inhibitor that binds to the colchicine site on tubulin, induces cell cycle arrest at the G2 M phase and triggers apoptosis, exhibiting anticancer activity by preventing tumor generation and inhibiting tumor proliferation and angiogenesis [1].

Tubulin polymerization-IN-47 is a tubulin polymerization inhibitor and mitotic inhibitor with antitumor activity and inhibitory effects on neuroblastoma cancer cell proliferation, with IC50s of 7 and 12 nM for Chp-134 and Kelly cell lines, respectively. Tubulin polymerization-IN-47 is a candidate compound for the treatment of hepatocellular carcinoma, colon cancer, lung cancer and breast cancer.

Tubulin polymerization-IN-37 is a potent inhibitor (IC50: 2.3 µM) of tubulin polymerization, binding specifically to the colchicine site of tubulin and preventing colchicine binding, with potential applications in cancer research, notably for lymphomas [1].

Tubulin aggregation-IN-17 (compound 23g) is a potent inhibitor of tubulin aggregation with microtubulin-depolymerising effects. It induces apoptosis, inhibits migration, and has significant potential for cancer disease research.

Tubulin aggregation-IN-18 (compound 3) is a potent tubulin aggregation inhibitor with potential for breast cancer and drug-resistant colon cancer studies.

Tubulin aggregation-IN-19 (compound 4) is a potent tubulin aggregation inhibitor that has shown potential in breast cancer and drug-resistant colon cancer.

Tubulin aggregation-IN-7 is a potent tubulin aggregation inhibitor that has shown research potential for cancer diseases.

Tubulin aggregation-IN-16 (compound 5g) is a potent inhibitor of tubulin aggregation that disrupts microtubule tubulin dynamics and induces G2 M phase cell cycle arrest in SGC-7901 cells.

Tubulin aggregation-IN-20 (compound 11) is a potent tubulin aggregation inhibitor with potential applications in the investigation of breast and drug-resistant colon cancer.